Top

Open Access 25-04-2024 | Epigenetics | Special supplement: MAFLD

The contribution of genetics and epigenetics to MAFLD susceptibility

Authors: Vittoria Moretti, Stefano Romeo, Luca Valenti

Abstract

Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common liver disease worldwide. The risk of developing MAFLD varies among individuals, due to a combination of environmental inherited and acquired genetic factors. Genome-wide association and next-generation sequencing studies are leading to the discovery of the common and rare genetic determinants of MAFLD. Thanks to the great advances in genomic technologies and bioinformatics analysis, genetic and epigenetic factors involved in the disease can be used to develop genetic risk scores specific for liver-related complications, which can improve risk stratification. Genetic and epigenetic factors lead to the identification of specific sub-phenotypes of MAFLD, and predict the individual response to a pharmacological therapy. Moreover, the variant transcripts and protein themselves represent new therapeutic targets. This review will discuss the current status of research into genetic as well as epigenetic modifiers of MAFLD development and progression.

Eslam M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73(1):202–209. https://doi.org/10.1016/j.jhep.2020.03.039CrossRefPubMed

Serfaty L, Lemoine M. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. Diabetes Metab 2008;34(6 Part 2):634–637. https://doi.org/10.1016/S1262-3636(08)74597-XCrossRefPubMed

Rinella ME, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023. https://doi.org/10.1016/j.jhep.2023.06.003CrossRefPubMed

Ilyas F, et al. Increasing nonalcoholic fatty liver disease–related mortality rates in the United States from 1999 to 2022. Hepatol Commun 2023;7(7):e00207. https://doi.org/10.1097/hc9.0000000000000207CrossRefPubMedPubMedCentral

Kaya E, Yilmaz Y. Metabolic-associated fatty liver disease (MAFLD): a multi-systemic disease beyond the liver. J Clin Transl Hepatol 2022;10(2):329–338. https://doi.org/10.14218/JCTH.2021.00178CrossRefPubMed

Rocha R, Cotrim HP, Carvalho FM, Siqueira AC, Braga H, Freitas LA. Body mass index and waist circumference in non-alcoholic fatty liver disease. J Hum Nutr Diet 2005;18(5):365–370. https://doi.org/10.1111/j.1365-277X.2005.00634.xCrossRefPubMed

Juanola O, Martínez-López S, Francés R, Gómez-Hurtado I. Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors. Int J Environ Res Public Health 2021;18(10):5227. https://doi.org/10.3390/ijerph18105227CrossRefPubMedPubMedCentral

Valenti L, Ronzoni L. Genetics: a new clinical tool for the hepatologist. Liver Int 2022;42(4):724–726. https://doi.org/10.1111/liv.15205CrossRefPubMed

Trépo E, Valenti L. Update on NAFLD genetics: from new variants to the clinic. J Hepatol 2020;72(6):1196–1209. https://doi.org/10.1016/j.jhep.2020.02.020CrossRefPubMed

10.

Pelusi S, et al. Clinical exome sequencing for diagnosing severe cryptogenic liver disease in adults: a case series. Liver Int 2022;42(4):864–870. https://doi.org/10.1111/liv.15185CrossRefPubMed

11.

Zheng M et al. Advancing diagnosis and management of liver disease in adults through exome sequencing. EBioMedicine 2023;95:104747. [Online]. Available: https://pan.ukbb.broadinstitute.org/

12.

Caussy C, et al. Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. J Clin Invest 2017;127(7):2697–2704. https://doi.org/10.1172/JCI93465CrossRefPubMedPubMedCentral

13.

Loomba R, et al. Heritability of hepatic fibrosis and steatosis based on a prospective twin study. Gastroenterology 2015;149(7):1784–1793. https://doi.org/10.1053/j.gastro.2015.08.011CrossRefPubMed

14.

Schwimmer JB, et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009;136(5):1585–1592. https://doi.org/10.1053/j.gastro.2009.01.050CrossRefPubMed

15.

Long MT, et al. Parental non-alcoholic fatty liver disease increases risk of non-alcoholic fatty liver disease in offspring. Liver Int 2019;39(4):740–747. https://doi.org/10.1111/liv.13956CrossRefPubMed

16.

Dongiovanni P, et al. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. J Intern Med 2018;283(4):356–370. https://doi.org/10.1111/joim.12719CrossRefPubMed

17.

Guerrero R, Vega GL, Grundy SM, Browning JD. Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology 2009;49(3):791–801. https://doi.org/10.1002/hep.22726CrossRefPubMed

18.

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2015. https://doi.org/10.1002/hep.28431/suppinfoCrossRefPubMed

19.

Kubiliun MJ, Cohen JC, Hobbs HH, Kozlitina J. Contribution of a genetic risk score to ethnic differences in fatty liver disease. Liver Int 2022;42(10):2227–2236. https://doi.org/10.1111/liv.15322CrossRefPubMedPubMedCentral

20.

Romeo S, Valenti L. African genetic ancestry and protection against fatty liver disease. Liver Int 2022;42:2122–2123CrossRefPubMed

21.

Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol 2018;68:268–279CrossRefPubMed

22.

Romeo S, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40(12):1461–1465. https://doi.org/10.1038/ng.257CrossRefPubMedPubMedCentral

23.

Kozlitina J, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014;46(4):352–356. https://doi.org/10.1038/ng.2901CrossRefPubMedPubMedCentral

24.

Speliotes EK, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011;7(3):e1001324. https://doi.org/10.1371/journal.pgen.1001324CrossRefPubMedPubMedCentral

25.

Mancina RM, et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of european descent. Gastroenterology 2016;150(5):1219–1230.e6. https://doi.org/10.1053/j.gastro.2016.01.032CrossRefPubMed

26.

Sookoian S, Pirola CJ, Valenti L, Davidson NO. Genetic pathways in nonalcoholic fatty liver disease: insights from systems biology. Hepatology 2020;72(1):330–346. https://doi.org/10.1002/hep.31229CrossRefPubMed

27.

Dongiovanni P, et al. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol 2013;19(41):6969–6978. https://doi.org/10.3748/wjg.v19.i41.6969CrossRefPubMedPubMedCentral

28.

Grimaudo S, et al. Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2020;18(4):935–944.e3. https://doi.org/10.1016/j.cgh.2019.08.011CrossRefPubMed

29.

Li BT, et al. Disruption of the ERLIN–TM6SF2–APOB complex destabilizes APOB and contributes to non-alcoholic fatty liver disease. PLoS Genet 2020;16(8):e1008955. https://doi.org/10.1371/JOURNAL.PGEN.1008955CrossRefPubMedPubMedCentral

30.

Prill S, et al. The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids. Sci Rep 2019;9(1):11585. https://doi.org/10.1038/s41598-019-47737-wCrossRefPubMedPubMedCentral

31.

Smagris E, Gilyard S, BasuRay S, Cohen JC, Hobbs HH. Inactivation of Tm6sf2, a gene defective in fatty liver disease, impairs lipidation but not secretion of very low density lipoproteins. J Biol Chem 2016;291(20):10659–10676. https://doi.org/10.1074/jbc.M116.719955CrossRefPubMedPubMedCentral

32.

Liu YL, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun 2014;5:4309. https://doi.org/10.1038/ncomms5309CrossRefPubMed

33.

Pelusi S, et al. Rare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease. Sci Rep 2019;9(1):3682. https://doi.org/10.1038/s41598-019-39998-2CrossRefPubMedPubMedCentral

34.

Buch S, et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet 2015;47(12):1443–1448. https://doi.org/10.1038/ng.3417CrossRefPubMed

35.

Chen Y, et al. Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease. Nat Genet 2023. https://doi.org/10.1038/s41588-023-01497-6CrossRefPubMedPubMedCentral

36.

Sveinbjornsson G, et al. Multiomics study of nonalcoholic fatty liver disease. Nat Genet 2022;54(11):652–1663CrossRef

37.

Mancina RM, et al. PSD3 downregulation confers protection against fatty liver disease. Nat Metab 2022;4(1):60–75. https://doi.org/10.1038/s42255-021-00518-0CrossRefPubMedPubMedCentral

38.

Bianco C, et al. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. J Hepatol 2021;74(4):775–782. https://doi.org/10.1016/j.jhep.2020.11.024CrossRefPubMedPubMedCentral

39.

Bianco C, Tavaglione F, Romeo S, Valenti L. Genetic risk scores and personalization of care in fatty liver disease. Curr Opin Pharmacol 2021;61:6–11. https://doi.org/10.1016/j.coph.2021.08.014CrossRefPubMed

40.

De Vincentis A, et al. A polygenic risk score to refine risk stratification and prediction for severe liver disease by clinical fibrosis scores. Clin Gastroenterol Hepatol 2022;20(3):658–673. https://doi.org/10.1016/j.cgh.2021.05.056CrossRefPubMed

41.

Haas ME, et al. Machine learning enables new insights into genetic contributions to liver fat accumulation. Cell Genomics 2021;1(3):100066. https://doi.org/10.1016/j.xgen.2021.100066CrossRefPubMedPubMedCentral

42.

Burnett JR, Hooper AJ, Hegele RA. APOB-related familial hypobetalipoproteinemia. GeneReviews® [Internet] 2021;1993–2023

43.

Grove JI, et al. Identification and characterisation of a rare MTTP variant underlying hereditary non-alcoholic fatty liver disease. JHEP Rep 2023;5(8):100764. https://doi.org/10.1016/j.jhepr.2023.100764CrossRefPubMedPubMedCentral

44.

Dongiovanni P, et al. PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. J Lipid Res 2019;60(6):1144–1153. https://doi.org/10.1194/jlr.P090449CrossRefPubMedPubMedCentral

45.

Wojcik GL, et al. Genetic analyses of diverse populations improves discovery for complex traits. Nature 2019;570(7762):514–518. https://doi.org/10.1038/s41586-019-1310-4CrossRefPubMedPubMedCentral

46.

Chen Z, Tian R, She Z, Cai J, Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med 2020;152:116–141. https://doi.org/10.1016/j.freeradbiomed.2020.02.025CrossRefPubMed

47.

Valenti L, et al. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2010;138(3):905–912. https://doi.org/10.1053/j.gastro.2009.11.013CrossRefPubMed

48.

Milic S, et al. The role of iron and iron overload in chronic liver disease. Med Sci Monit 2016;22:2144–2151. https://doi.org/10.12659/MSM.896494CrossRefPubMedPubMedCentral

49.

Corradini E, et al. Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. J Hepatol 2021;75(3):506–513. https://doi.org/10.1016/j.jhep.2021.03.014CrossRefPubMed

50.

Vujkovic M, et al. A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. Nat Genet 2022;54(6):761–771. https://doi.org/10.1038/s41588-022-01078-zCrossRefPubMedPubMedCentral

51.

Petta S, et al. Fibronectin type III domain-containing protein 5 rs3480 A>G polymorphism, irisin, and liver fibrosis in patients with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2017;102(8):2660–2669. https://doi.org/10.1210/jc.2017-00056CrossRefPubMed

52.

Metwally M, et al. A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3′UTR. J Hepatol 2019;70(3):494–500. https://doi.org/10.1016/j.jhep.2018.10.021CrossRefPubMed

53.

Petta S, et al. Interferon lambda 4 rs368234815 TT>dG variant is associated with liver damage in patients with nonalcoholic fatty liver disease. Hepatology 2017;66:1885–1893. https://doi.org/10.1002/hep.29395/suppinfoCrossRefPubMed

54.

Eslam M, Ahlenstiel G, George J. Interferon lambda and liver fibrosis. J Interf Cytokine Res 2019;39(10):627–635CrossRef

55.

Kitamoto A, et al. Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits. Endocr J 2014;64(7):683–689CrossRef

56.

Dongiovanni P, et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut 2010;59(2):267–273CrossRefPubMed

57.

Abul-Husn NS, et al. A protein-truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med 2018;378(12):1096–1106. https://doi.org/10.1056/nejmoa1712191CrossRefPubMedPubMedCentral

58.

Baselli GA, et al. Rare ATG7 genetic variants predispose patients to severe fatty liver disease. J Hepatol 2022;77(3):596–606. https://doi.org/10.1016/j.jhep.2022.03.031CrossRefPubMed

59.

Calado RT, et al. A spectrum of severe familial liver disorders associate with telomerase mutations. PLoS ONE 2009;4(11):e7926. https://doi.org/10.1371/journal.pone.0007926CrossRefPubMedPubMedCentral

60.

Stender S, Kozlitina J, Nordestgaard BG, Tybjærg-Hansen A, Hobbs HH, Cohen JC. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet 2017;49(6):842–847. https://doi.org/10.1038/ng.3855CrossRefPubMedPubMedCentral

61.

Tavaglione F, Jamialahmadi O, Valenti L, Romeo S. Fatty liver disease genetic risk variants and interference on sex hormones. Liver Int 2023;43(5):958–961. https://doi.org/10.1111/liv.15562CrossRefPubMed

62.

Jaruvongvanich V, Sanguankeo A, Riangwiwat T, Upala S. Testosterone, sex hormone-binding globulin and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Ann Hepatol 2017;16(3):382–394. https://doi.org/10.5604/16652681.1235481CrossRefPubMed

63.

Falzarano C, et al. Nonalcoholic fatty liver disease in women and girls with polycystic ovary syndrome. J Clin Endocrinol Metab 2022;107(1):258–272. https://doi.org/10.1210/clinem/dgab658CrossRefPubMed

64.

Cherubini A, et al. Interaction between estrogen receptor-α and PNPLA3 p. I148M variant drives fatty liver disease susceptibility in women. Nat Med 2023;29:2643–2655. https://doi.org/10.1038/s41591-023-02553-8CrossRefPubMedPubMedCentral

65.

Shen M, Shi H. Sex hormones and their receptors regulate liver energy homeostasis. Int J Endocrinol 2015;2015:294278. https://doi.org/10.1155/2015/294278CrossRefPubMedPubMedCentral

66.

Brunner SF, et al. Somatic mutations and clonal dynamics in healthy and cirrhotic human liver. Nature 2019;574:538–542. https://doi.org/10.17632/ktx7jp8sch.1CrossRefPubMedPubMedCentral

67.

Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 2015;149(5):1226–1239.e4. https://doi.org/10.1053/j.gastro.2015.05.061CrossRefPubMed

68.

Valenti L, Romeo S, Pajvani U. A genetic hypothesis for burnt-out steatohepatitis. Liver Int 2021;41(12):2816–2818. https://doi.org/10.1111/liv.15103CrossRefPubMed

69.

Ng SWK, et al. Convergent somatic mutations in metabolism genes in chronic liver disease. Nature 2021;598(7881):473–478. https://doi.org/10.1038/s41586-021-03974-6CrossRefPubMed

70.

Garcia-Lezana T, Lopez-Canovas JL, Villanueva A. Signaling pathways in hepatocellular carcinoma. Adv Cancer Res 2021;149:63–101. https://doi.org/10.1016/bs.acr.2020.10.002CrossRefPubMed

71.

Nault JC, et al. Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation. Gastroenterology 2017;152(4):880–894.e6. https://doi.org/10.1053/j.gastro.2016.11.042CrossRefPubMed

72.

Donati B, Valenti L. Telomeres, NAFLD and chronic liver disease. Int J Mol Sci 2016;17(3):383. https://doi.org/10.3390/ijms17030383CrossRefPubMedPubMedCentral

73.

Muller PAJ, Vousden KH. P53 mutations in cancer. Nat Cell Biol 2013;15(1):2–8. https://doi.org/10.1038/ncb2641CrossRefPubMed

74.

Rebouissou S, et al. Proliferation markers are associated with MET expression in hepatocellular carcinoma and predict tivantinib sensitivity in vitro. Clin Cancer Res 2017;23(15):4364–4375. https://doi.org/10.1158/1078-0432.CCR-16-3118CrossRefPubMed

75.

Satoh S, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. 2000. [Online]. Available: http://genetics.nature.com/supplementary_info/

76.

Genovese G, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014;371(26):2477–2487. https://doi.org/10.1056/nejmoa1409405CrossRefPubMedPubMedCentral

77.

Wong WJ, et al. Clonal hematopoiesis and risk of chronic liver disease. Nature 2023;616:747–754. https://doi.org/10.1101/2022.01.17.22269409CrossRefPubMedPubMedCentral

78.

Kessler MD, et al. Common and rare variant associations with clonal haematopoiesis phenotypes. Nature 2022;612(7939):301–309. https://doi.org/10.1038/s41586-022-05448-9CrossRefPubMedPubMedCentral

79.

Ferrari A, et al. Epigenome modifiers and metabolic rewiring: new frontiers in therapeutics. Pharmacol Ther 2019;193:178–193. https://doi.org/10.1016/j.pharmthera.2018.08.008CrossRefPubMed

80.

Mwinyi J, et al. NAFLD is associated with methylation shifts with relevance for the expression of genes involved in lipoprotein particle composition. Biochim Biophys Acta Mol Cell Biol Lipids 2017;1862(3):314–323. https://doi.org/10.1016/j.bbalip.2016.12.005CrossRefPubMed

81.

Pirola CJ, et al. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut 2013;62(9):1356–1363. https://doi.org/10.1136/gutjnl-2012-302962CrossRefPubMed

82.

Lee JH, Friso S, Choi SW. Epigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutrition. Nutrients 2014;6(8):3303–3325. https://doi.org/10.3390/nu6083303CrossRefPubMedPubMedCentral

83.

Murphy SK, et al. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterology 2013;145(5):1076–1087. https://doi.org/10.1053/j.gastro.2013.07.047CrossRefPubMed

84.

de Mello VD, et al. Human liver epigenetic alterations in non-alcoholic steatohepatitis are related to insulin action. Epigenetics 2017;12(4):287–295. https://doi.org/10.1080/15592294.2017.1294305CrossRefPubMedPubMedCentral

85.

Kitamoto T, et al. Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease. [Online]. Available: http://www.bioinformatics.babraham.ac.uk/projects/fastqc/

86.

Donati B, et al. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage. Hepatology 2015. https://doi.org/10.1002/hep.28370/suppinfoCrossRef

87.

Hotta K, et al. Identification of the genomic region under epigenetic regulation during non-alcoholic fatty liver disease progression. Hepatol Res 2018;48(3):E320–E334. https://doi.org/10.1111/hepr.12992CrossRefPubMed

88.

Gerhard GS, et al. Differentially methylated loci in NAFLD cirrhosis are associated with key signaling pathways. Clin Epigenet 2018;10(1):93. https://doi.org/10.1186/s13148-018-0525-9CrossRef

89.

Klose RJ, Kallin EM, Zhang Y. JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet 2006;7(9):715–727. https://doi.org/10.1038/nrg1945CrossRefPubMed

90.

Ferrante AW. Improving metabolism by throwing out all the JNK. Science 2013;339(6116):147–148. https://doi.org/10.1126/science.1233223CrossRefPubMed

91.

Bricambert J, Miranda J, Benhamed F, Girard J, Postic C, Dentin R. Salt-inducible kinase 2 links transcriptional coactivator p300 phosphorylation to the prevention of ChREBP-dependent hepatic steatosis in mice. J Clin Invest 2010;120(12):4316–4331. https://doi.org/10.1172/JCI41624CrossRefPubMedPubMedCentral

92.

Li Y, et al. Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21. Gastroenterology 2014;146(2):539–549. https://doi.org/10.1053/j.gastro.2013.10.059CrossRefPubMed

93.

Dongiovanni P, Meroni M, Longo M, Fargion S, Fracanzani AL. MiRNA signature in NAFLD: a turning point for a non-invasive diagnosis. Int J Mol Sci 2018;19(12):3966. https://doi.org/10.3390/ijms19123966CrossRefPubMedPubMedCentral

94.

Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 2013;10(9):542–552. https://doi.org/10.1038/nrgastro.2013.87CrossRefPubMedPubMedCentral

95.

Horvath S, et al. Obesity accelerates epigenetic aging of human liver. Proc Natl Acad Sci U S A 2014;111(43):15538–15543. https://doi.org/10.1073/pnas.1412759111CrossRefPubMedPubMedCentral

96.

Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS ONE 2011;6(8):e23937. https://doi.org/10.1371/journal.pone.0023937CrossRefPubMedPubMedCentral

97.

Pogribny IP, et al. Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab Investig 2010;90(10):1437–1446. https://doi.org/10.1038/labinvest.2010.113CrossRefPubMed

98.

Jampoka K, Muangpaisarn P, Khongnomnan K, Treeprasertsuk S, Tangkijvanich P, Payungporn S. Serum miR-29a and miR-122 as potential biomarkers for non-alcoholic fatty liver disease (NAFLD). Microrna 2018;7(3):215–222CrossRefPubMed

99.

Yu J, Peng J, Luan Z, Zheng F, Su W. MicroRNAs as a novel tool in the diagnosis of liver lipid dysregulation and fatty liver disease. Molecules 2019;24(2):230. https://doi.org/10.3390/molecules24020230CrossRefPubMedPubMedCentral

100.

He Y, Huang C, Zhang S, Sun X, Long X, Li J. The potential of microRNAs in liver fibrosis. Cell Signal 2012;24(12):2268–2272. https://doi.org/10.1016/j.cellsig.2012.07.023CrossRefPubMed

Title: The contribution of genetics and epigenetics to MAFLD susceptibility
Authors: Vittoria Moretti
Stefano Romeo
Luca Valenti
Publication date: 25-04-2024
Publisher: Springer India
Keywords: Epigenetics
Hepatocellular Carcinoma
Hepatocellular Carcinoma
Insulins
Insulins
Published in: Hepatology International
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-024-10667-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com